@entity1124 is the fourth leading cause of @entity5 -related mortality in the western countries for both @entity1 and @entity1 . Until in 2015, it remains one of the most challenging @entity5 with a dismal prognosis and limited therapeutic options. The 5-year survival rate for @entity788 is around 5%, which is the lowest among all different @entity5 sites. The poor prognosis of PDAC is largely attributed to delayed diagnosis due to nonspecific symptoms in the early stages of the disease, @entity146 leading to rapid @entity3 , lack of effective screening methods, and resistance to radiation and chemotherapies. In the event of @entity3 , @entity1 were traditionally referred to palliative treatments. Thanks to continuous progresses in the surgical expertise, synchronous and metachronous @entity3 resections seem technically feasible nowadays. These reports describe 2 several clinical cases in which @entity1 with @entity788 , and synchronous and metachronous liver @entity3 respectively, were treated with a surgical approach. @entity1 showed a better survival rate compared current data in the literature. Our results, often in conflict with the guidelines and recent evidences, confirm the need for a new vision of the @entity3 "problem" in @entity1 with @entity788 . KEY WORDS: Metastases, @entity788 , Surgical resection.

Surgical resection of synchronous and metachronous @entity3 from XXXX . Two case reports in the light of recent evidences.

@entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients', 'men'] @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatic cancer', 'Pancreatic Adenocarcinoma'] @entity1124 :: ('MESH:D021441', 'Disease') :: ['Pancreatic ductal adenocarcinoma'] @entity146 :: ('MESH:D001523', 'Disease') :: ['biological aggressiveness'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'malignancies'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases']
@entity788 :: (MESH:D010190,Disease) :: ['pancreatic adenocarcinoma']
